Prospective and Randomized Analysis of Endoscopic Prostate Enucleation Using Moses 2.0 Technology Versus the New Thulium Fiber Laser in Medium and Large Prostates.

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Introduction: Endoscopic anatomical enucleation of the prostate (EEAP) with lasers has emerged as an effective and less invasive surgical option compared to traditional methods. Among the various available laser options, Holmium laser and Thulium Fiber laser have stood out as two prominent approaches for performing endoscopic prostate enucleation. These technologies have 3 showcased their effectiveness in ablating prostatic tissue and improving urinary symptoms. Nevertheless, differences in their physical properties and modes of action may impact their success rates and clinical outcomes. In our institution it is standard practice to use one laser or the other according to their availability in the operating room. Primary

Objective: To demonstrate the superiority of MoLEP over ThuFLEP in terms of enucleation efficiency. Secondary

Objectives: a) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of perioperative bleeding. b) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of postoperative hospital stay. c) To demonstrate the non-inferiority of ThuFLEP compared to ThuFLEP in terms of perioperative complications. d) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of improvement in urinary symptoms. e) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of improvement in flowmetric variables. Study Type: Prospective, randomized, non-blind, multicentric clinical trial. Intervention: Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 40
Maximum Age: 90
Healthy Volunteers: f
View:

• Males aged between 40 and 90 years.

• Patients who, due to their lower urinary tract symptoms, are candidates for

∙ BPH surgery, including:

• Obstructive urinary symptoms evaluated through IPSS with a score \>7 and QoL \> 2 or acute urinary reten on refractory to catheter removal.

• Obstructive urinary flow evaluated through uroflowmetry with Qmax\< 15 ml/s, obstruction demonstrated by pressure/flow study, prostatic origin haematuria refractory to medical treatment, or acute urinary retention refractory to catheter removal.

‣ Prostatic volume measured by transabdominal ultrasound, transrectal ultrasound, or magnetic resonance imaging of more than 80 cc.

⁃ Prostate-specific antigen (PSA) \< 4 ng/ml, or with multiparametric prostate magnetic resonance imaging reporting PIRADS \< 3 or equal to 3 with PSA density \< 15%.

Locations
Other Locations
Spain
Clinic Hospital of Barcelona
RECRUITING
Barcelona
Fundacio Puigvert
RECRUITING
Barcelona
Hospital Univesitari de Bellvitge
NOT_YET_RECRUITING
L'hospitalet De Llobregat
Contact Information
Primary
Ivan Schwartzmann Jochamowitz, MD
ischwartzm@fundacio-puigvert.es
0034934169700
Backup
Silvia Mateu, MD
smateu@fundacio-puigvert.es
0034934169700
Time Frame
Start Date: 2024-09-03
Estimated Completion Date: 2028-09
Participants
Target number of participants: 120
Treatments
Active_comparator: Endoscopic Prostate Enucleation Using Moses 2.0 Technology
Pulse modulation technology in Moses 2.0 applied to Holmium Laser Endoscopic Prostate (MoLEP).
Active_comparator: Endoscopic Prostate Enucleation Using the New Thulium Fiber Laser
Thulium Fiber laser to endoscopic prostate enucleation (ThuFLEP).
Related Therapeutic Areas
Sponsors
Leads: Fundacio Puigvert

This content was sourced from clinicaltrials.gov